The growth of the companion diagnostics market is largely driven by the sharp worldwide rise in cancer incidence. Increasing awareness of precision medicine among patients, along with manufacturers' expanding efforts to advance precision-based treatments, has further strengthened the demand for companion diagnostics. In addition, intensified R&D aimed at creating companion tests for non-cancer conditions, together with a surge in product approvals and new launches, are expected to significantly propel the global companion diagnostics market throughout the forecast period (2025–2032).

LAS VEGAS, March 5, 2026 /PRNewswire/ -- DelveInsight's Companion Diagnostics Market Insights report provides the current and forecast market analysis, individual leading companion diagnostics companies' market shares, challenges, companion diagnostics market drivers, barriers, trends, and key companion diagnostics companies in the market.

Companion Diagnostics Market Summary

• 2024 Companion Diagnostics Market Size: ~USD 6 Billion
• 2032 Projected Companion Diagnostics Market Size: ~USD 12 Billion
• Companion Diagnostics Market Growth Rate (2025-2032): ~12% 
• Largest Companion Diagnostics Market: North America
• Largest Product Type Segment: Assays, Kits & Reagents Subsegment
• Key Companies in the Companion Diagnostics Market: Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott Laboratories, QIAGEN, BIOMÉRIEUX, Guardant Health Inc., Illumina, Inc., Pillar Biosciences, Inc., Leica Biosystems, Thermo Fisher Scientific Inc., Almac Group, NeoGenomics Laboratories, Invitae Corporation, 3D Medicines Corporation, ASURAGEN, INC. (Biotechne), Invivoscribe, Inc., Amoy Diagnostics Co., Ltd., Laboratory Corporation of America® Holdings, SAGA Diagnostics, and others

To read more about the latest highlights related to the companion diagnostics market, get a snapshot of the key highlights @ https://www.delveinsight.com/sample-request/companion-diagnostics-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Contributing to the Rise in Growth of the Companion Diagnostics Market

• Increasing Adoption of Targeted Therapies: The shift from "one-size-fits-all" medicine to personalized treatment strategies is a major driver. Targeted therapies often require a diagnostic test to identify whether a patient will respond to a specific drug.
• Rising Prevalence of Cancer and Chronic Diseases: Cancer, cardiovascular diseases, and autoimmune disorders increasingly require biomarkers for accurate treatment selection. As disease prevalence rises globally, demand for precise biomarker-based decision-making continues to accelerate.
• Regulatory Encouragement and Approval Pathways: Regulatory bodies such as the FDA have strengthened frameworks encouraging co-development of drugs and companion diagnostics. Clearer pathways reduce uncertainty and promote innovation.
• Growth in Precision Medicine Initiatives: Governments and research institutions globally are investing in precision medicine programs. Such initiatives increase genetic testing, biomarker discovery, and clinical trial integration of diagnostics with therapies.
• Advances in Genomic Technologies: Technological improvements such as next-generation sequencing (NGS), liquid biopsy, and multiplex assays enable faster, more accurate, and cost-effective testing. 
• Increasing Drug–Diagnostic Co-Development Partnerships: Pharmaceutical companies increasingly collaborate with diagnostic manufacturers to ensure that targeted therapies are matched with reliable tests. These cross-industry partnerships accelerate market expansion and regulatory alignment.
• Growing Demand for Personalized Oncology Solutions: Oncology remains the largest segment driving adoption. Companion diagnostics help determine suitability for immunotherapies, targeted therapies, and emerging precision-oncology regimens. This improves patient outcomes and reduces unnecessary treatment costs.
• Expansion of Clinical Trials Requiring Biomarker Testing: Clinical trials are increasingly incorporating biomarker-driven patient selection. This rising integration increases demand for validated assays that can stratify patient populations based on genetic or molecular features.

Regional Companion Diagnostics Market Insights

North America

• North America continues to dominate the companion diagnostics market, driven by strong adoption of precision medicine, high cancer prevalence, and a favorable regulatory environment.
• The presence of major diagnostic developers, well-established healthcare infrastructure, and faster approvals for biomarker-based tests further accelerate regional growth. 
• Reimbursement support for genomic testing and the rapid penetration of next-generation sequencing (NGS) panels also strengthen market expansion.

Europe

• Europe holds the second-largest share, supported by rising demand for targeted therapies and harmonized regulatory pathways for in vitro diagnostics. 
• The region benefits from strong government initiatives promoting personalized medicine and increased investments in molecular diagnostics. 
• Adoption is especially high in Western Europe, where healthcare systems increasingly integrate companion diagnostics for oncology and rare diseases.

Asia-Pacific

• Asia-Pacific exhibits the fastest growth in the global market. Factors such as improving healthcare access, rising cancer burden, and expanding clinical trial activity drive demand. 
• Countries including China, Japan, and South Korea are seeing rapid integration of NGS-based companion diagnostics, supported by government funding and growing domestic biotech ecosystems. 
• Increasing awareness of precision therapies among physicians and patients also contributes to market momentum.

Latin America

• The Latin American market is gradually expanding, with adoption primarily concentrated in major markets such as Brazil, Mexico, and Argentina. 
• Key drivers include improving diagnostic capabilities, growing private healthcare investments, and rising access to targeted oncology drugs. 
• However, limited reimbursement frameworks and uneven infrastructure across the region remain challenges.

Middle East & Africa

• The Middle East & Africa region is in an early growth phase but shows increasing potential. Gulf countries are investing heavily in advanced diagnostic technologies and precision oncology centers, boosting adoption. 
• However, broader market expansion is constrained by limited molecular testing infrastructure, low awareness, and budgetary pressures in several African countries. 
• Over time, greater collaborations with global diagnostics developers and rising cancer incidence are expected to support demand.

Get a sneak peek at the companion diagnostics market dynamics @ Companion Diagnostics Market Trends

Recent Developmental Activities in the Companion Diagnostics Market

• In March 2026, Quest Diagnostics introduced Quest AI Companion, an AI-driven chat tool designed to help people interpret their Quest lab test results and decide on next steps in collaboration with their healthcare provider.
• In February 2026, Agilent Technologies obtained FDA clearance for its PD-L1 IHC 22C3 pharmDx assay to be used as a companion diagnostic for individuals with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• In February 2026, the National Medical Products Administration granted Class III in-vitro diagnostic approval in China for the OncoMate Microsatellite Instability Detection Kit.
• In January 2026, Guardant Health, Inc. announced that the U.S. FDA had authorized the Guardant360® CDx test to be used as a companion diagnostic for identifying patients with metastatic colorectal cancer harboring a BRAF V600E mutation who may be eligible for treatment with BRAFTOVI® (encorafenib) combined with cetuximab and chemotherapy, as outlined in the approved labeling.

What are Companion Diagnostics?

Companion diagnostics are specialized medical tests designed to identify whether a particular patient is likely to benefit from a specific drug or therapy. By analyzing biomarkers, such as genetic mutations, protein levels, or other molecular indicators, these tests help determine how an individual's body will respond to targeted treatments. This allows clinicians to personalize therapy, select the most effective medication, and avoid treatments that may be ineffective or cause unnecessary side effects. As a key component of precision medicine, companion diagnostics improve treatment outcomes by ensuring that the right patient receives the right therapy at the right time.

Companion Diagnostics Market Assessment

• Companion Diagnostics Market Segmentation
• Companion Diagnostics Market Segmentation By Type: Product [Assays, Kits & Reagents And Instruments], and Services
• Companion Diagnostics Market Segmentation By Technology: Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Others
• Companion Diagnostics Market Segmentation By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, and Others
• Companion Diagnostics Market Segmentation By End-User: Hospitals, Diagnostic Labs, and Others
• Companion Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Which MedTech key players in the companion diagnostics market are set to emerge as the trendsetter explore @ Companion Diagnostics Market Analysis

Table of Contents 

Interested in knowing the companion diagnostics market share by 2032? Click to get a snapshot of the Companion Diagnostics Market Size 

Related Reports

Molecular Diagnostics Market

Molecular Diagnostics Market Insights, Competitive Landscape and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key molecular diagnostics companies, including Hoffmann-La Roche Ltd., Hologic, Inc., bioMérieux SA, Abbott, QIAGEN, BD, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher, Myriad Genetics, Inc., Agilent Technologies Inc., Illumina Inc., DiaSorin Inc., MDxHealth, Genetic Signatures, Biocartis, Exact Sciences Corporation, Amoy Diagnostics Co. Ltd., Molbio Diagnostics Pvt. Ltd., Savyon Diagnostics, and others.

AI in Medical Diagnostics Market

AI in Medical Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical diagnostics companies, including GE HealthCare, Aidoc, Qure.ai, Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Tecomet Inc., Prenosis, Inc., Riverain Technologies, Envisionit Deep AI (Pty) Ltd., Deep Bio, Inc., and others.

AI in Diagnostics Market

AI in Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key AI in diagnostics companies, including Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others.

AI in Cancer Diagnostics Market

AI in Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key AI in cancer diagnostics companies, including iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Onc.AI, Sonrai Analytics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

Contact Us

Shruti Thakur

info@delveinsight.com

+14699457679 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/global-companion-diagnostics-market-to-register-immense-growth-at-a-cagr-of-12-by-2032--delveinsight-302704875.html

Die Panne im E-Voting-System des Kantons Basel-Stadt setzt dem digitalen Abstimmen in der Schweiz vorerst enge Grenzen – aber nicht überall. Nachdem bei der eidgenössischen Volksabstimmung vom 8. März 2026 insgesamt 2048 elektronisch abgegebene Stimmen in Basel-Stadt wegen einer nicht entschlüsselbaren «elektronischen Urne» verloren gingen, stoppt der Stadtkanton seinen Versuchsbetrieb bis Ende 2026. Die Bundeskanzlei spricht von einer schweren Verletzung der politischen Rechte der Betroffenen, sieht derzeit aber keinen Anlass, den gesamtschweizerischen Versuchsbetrieb grundsätzlich infrage zu stellen.

Auslöser des Vorfalls war nach kantonalen Angaben ein Problem im Umgang mit einem USB-Datenträger, der im Auszählprozess eine Rolle spielte. Die Folge: Sämtliche elektronisch eingereichten Stimmen aus Basel-Stadt – darunter zahlreiche Auslandschweizerinnen und -schweizer – konnten nicht gezählt werden. Angesichts der klaren provisorischen Abstimmungsergebnisse schliessen die Behörden aus, dass sich die Mehrheitsentscheide dadurch verändert hätten. Politisch unverändert bleibt der Schaden dennoch erheblich: Stimmberechtigte wie die im Elsass wohnhafte Christine D'Souza kritisieren die späte Information und prüfen rechtliche Schritte wegen Verletzung ihrer politischen Rechte.

Der Regierungsrat von Basel-Stadt will die Ursachen des Vorfalls extern untersuchen lassen; die Staatsanwaltschaft hat wegen eines Anfangsverdachts auf ein Offizialdelikt ein Strafverfahren eröffnet. Parallel dazu hat der Kanton seine Teilnahme am E-Voting-Versuchsbetrieb bis zum 31. Dezember 2026 ausgesetzt, um Abläufe zu überprüfen und Korrekturmassnahmen zu erarbeiten. Die Bundeskanzlei begrüsst sowohl die externe Analyse als auch das strafrechtliche Vorgehen und betont, es müssten alle notwendigen Schritte unternommen werden, um eine Wiederholung zu verhindern.

Während Basel auf die Bremse tritt, halten andere Versuchskantone demonstrativ Kurs. Thurgau, Graubünden und St. Gallen erklärten in einer gemeinsamen Mitteilung, sie führten ihre Pilotprojekte mit dem E-Voting-System der Schweizerischen Post unverändert weiter. Das System habe sich seit 2023 in allen Wahlen und Abstimmungen bewährt, heisst es. Auch am 8. März sei der Einsatz in den beteiligten Gemeinden, darunter Amriswil und Bischofszell, problemlos verlaufen. Der Basler Vorfall habe nichts mit dem E-Voting-System als solchem zu tun, sondern sei auf die Handhabung einer externen Komponente, eben jenes USB-Sticks, zurückzuführen.

Bund und Kantone verweisen darauf, dass sich E-Voting weiterhin in einem bewusst eng gefassten Versuchsbetrieb befindet. Dieser sei darauf ausgelegt, technische und organisatorische Schwachstellen frühzeitig zu identifizieren und Prozesse laufend zu verbessern. Gleichwohl warnen Politologen vor einem möglichen Vertrauensverlust in der Bevölkerung: Die Basler Panne liefert Gegnern des elektronischen Abstimmens ein anschauliches Beispiel für Risiken und dürfte die politische Debatte um Tempo und Umfang des weiteren Ausbaus verschärfen – gerade in jenen Kantonen, die ihr digitales Angebot eigentlich ausweiten wollten.